Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Urologic Neoplasms 1Urogenital Neoplasms 1Tuberculosis 1Hematuria 1Fever 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 6Pemetrexed 3Cisplatin 3Carboplatin 3atezolizumab 2Trastuzumab 2Sugammadex 2Paclitaxel 2Neostigmine 2vinflunine 1poly ICLC 1pembrolizumab 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1delta 24-sterol reductase 1daratumumab 1avelumab 1apatorsen 1abemaciclib 1Water 1Thalidomide 1Surveys and Questionnaires 1Saline Solution 1Rocuronium 1Nephroureterectomy 1Nephrectomy 1Neoadjuvant Therapy 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urologic Neoplasms × Administration, Intravesical × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔